Is Rituximab Ready for Prime Time in SSc? Experts: new data support rituximab for reducing lung fibrosis in systemic sclerosis.

Author: Diana Swift
Date Published: January-2015
Source: MedPage Today

B-cell depletion via rituximab (Rituxan) infusion reduced the progression of skin thickening and lung fibrosis in systemic sclerosis (SSc), according to a review article, and clinicians need to consider rituximab therapy in these patients. Fiona McQueen, MD, of the University of Auckland, and Kamal Solanki, MD, of Waikato Hospital in Hamilton, both in New Zealand, looked at observational, case-control data from the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) group and summarized their findings in Rheumatology.